Kirstin Finning
Papers
3
Total Citations
302
H-Index
3
About
Kirstin Finning is a pioneering researcher in non-invasive prenatal diagnostics, whose work has transformed the management of RhD incompatibility in pregnancy. Her key research focuses on fetal *RHD* genotyping from cell-free fetal DNA in maternal plasma, a breakthrough that enables targeted use of anti-RhD immunoglobulin. Finning’s most influential study, a 2008 prospective feasibility trial with 231 citations, demonstrated that high-throughput robotic *RHD* typing could reliably predict fetal RhD status, sparing RhD-negative women unnecessary treatment. This work, alongside a 2011 study on early gestation genotyping (53 citations), established a safe, scalable method to prevent hemolytic disease of the newborn. By reducing anti-RhD immunoglobulin administration by up to 40%, her contributions have improved maternal care efficiency and fetal outcomes globally. Finning’s research is widely cited for its clinical impact, merging molecular genetics with routine antenatal screening. Her achievements underscore a career dedicated to translating genomic innovation into practical, life-saving obstetrics.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3